SignalXSignalX

CRNX Crinetics Pharmaceuticals, Inc.

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Crinetics Pharmaceuticals, Inc. Overview

Crinetics Pharmaceuticals, Inc. (CRNX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No newly added risk factors this quarter; risks consistent with prior 10-K disclosures
  • • Most materially updated risk: increased operating losses due to PALSONIFY U.S. approval and EMA submission pre-commercialization activities
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$143,000

▼ -86.1% QoQ

Net Income

-$130M

▼ -69.3% YoY▼ -12.5% QoQ

Operating Margin

-99710.5%

▼ -8718750bp QoQ

Net Margin

-90972.7%

▼ -7975672bp QoQ

ROE

-12.1%

Total Assets

$1.2B

EPS (Diluted)

$-1.39

▼ -44.8% YoY▼ -13.0% QoQ

Operating Cash Flow

-$111M

▼ -76.2% YoY▼ -29.0% QoQ

Source: XBRL data from Crinetics Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Crinetics Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.